Oncology

2016 ◽  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Basic Science ◽  
Multidisciplinary Approach ◽  
Biological Therapy ◽  
Symptom Control ◽  
Diagnostic Techniques ◽  
Paraneoplastic Syndromes ◽  
Basic Training ◽  
Screening Strategies

Chapter 15 covers the basic science and clinical topics relating to oncology which trainees are required to learn as part of their basic training and demonstrate in the MRCP. It covers basic science, genetics in oncology, screening strategies in oncology, diagnostic techniques in oncology, oncological emergencies, breast cancer and lymphoma, prostate cancer, paraneoplastic syndromes, chemotherapy, biological therapy, and targeted therapy, radiotherapy, end of life: the multidisciplinary approach, and symptom control.

Breast Cancer and Anesthesia

2019 ◽  
Vol 25 (28) ◽  
pp. 2998-3004 ◽  
Author(s):  
Aida Raigon-Ponferrada ◽  
María E.D. Recio ◽  
Jose L. Guerrero-Orriach ◽  
Alfredo Malo-Manso ◽  
Juan J. Escalona-Belmonte ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multidisciplinary Approach ◽  
Biological Therapy ◽  
Comprehensive Treatment ◽  
Medical Oncologists

: Breast cancer is a complex heterogeneous disease that is categorized into several histological and genomic subtypes with relevant prognostic and therapeutical implications. Such diversity requires a multidisciplinary approach for a comprehensive treatment that will involve surgeons, radiotherapists and medical oncologists. Breast cancer is classified as either local (or locoregional), which stands for 90-95% of cases, or metastatic, representing 5% of cases. : The management of breast cancer will be determined by the stage of the disease. The treatment of local breast cancer is based on surgery and/or radiotherapy. Systemic breast cancer requires chemotherapy and/or endocrine and/or biological therapy.

“Prostate Cancer Unit” for an Optimal Management of Prostate Cancer

2012 ◽  
Vol 79 (1) ◽  
pp. 1-4
Author(s):  
Alessandro Sciarra ◽  
Stefano Salciccia ◽  
Alessandro Gentilucci ◽  
Michele Innocenzi ◽  
Andrea Alfarone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Multidisciplinary Approach ◽  
Healthcare Professionals ◽  
Male Population ◽  
Medical Problems ◽  
Adequate Information ◽  
Working Together ◽  
Prostate Cancers ◽  
To Receive

Prostate cancer (PC) is established as one of the most important medical problems affecting the male population. PC is the most common solid neoplasm (214 cases per 1000 men) and the second most common cause of cancer death in men. Its management involves several complex issues for both clinicians and patients. An early diagnosis is necessary to implement well-balanced therapeutic options, and the correct evaluation can reduce the risk of overtreatment with its consequential adverse effects. Breast and Prostate cancers, respectively, are the most common cancers in women and in men, and different similarities have been underlined. The paradigm of the patient consulting a multidisciplinary medical team has been an established standard approach in treating breast cancer. Such multidisciplinary approach can offer the same optional care for men with PC as it does for women with breast cancer. A multidisciplinary team (MDT) comprises healthcare professionals from different disciplines whose goal of providing optimal patient care is achieved through coordination and communication with one another. A Prostate Cancer Unit is a place where men can be cared for by specialists in PC, working together within a multi-professional team. The MTD approach guarantees a higher probability for the PC patient to receive adequate information on the disease and on all possible therapeutic strategies, balancing advantages and related side effects. The future of PC patients relies on a successful multidisciplinary collaboration between experienced physicians, which can lead to important advantages in all the phases and aspects of PC management.

scholarly journals The Importance of Multidisciplinary Cardio-Oncology Team in the Breast Cancer Treatment with Anthracyclines

2021 ◽  
Vol 18 (4) ◽  
pp. 67-75
Author(s):  
Diana-Lavinia Pricope ◽  
Florin Mitu
Keyword(s):  
Breast Cancer ◽  
Cardiovascular Disease ◽  
Cancer Treatment ◽  
Multidisciplinary Approach ◽  
Biological Therapy ◽  
Breast Cancer Treatment ◽  
Therapeutic Decision ◽  
Antitumoral Effect ◽  
Her2 Breast Cancer ◽  
Oncologic Treatment

Abstract The anthracyclines, represented by Doxorubicin, Epirubicin or Idarubicin, are paramount in Oncology due to their antitumoral efficacy in a multitude of solid cancers, making them essential in breast cancer treatment. The biggest disadvantage of anthracyclines, cardiotoxicity, happens as a direct effect of the oncologic treatment on the anatomy and the physiology of the heart and acts also as an element which advances pre-existent cardiovascular disease(2). We are presenting the case of a 51-year-old lady, clinically, with imagistic and biopsy diagnosis of breast cancer cT3N3M0, negative HR, HER 2neu-3+, that was treated with neoadjuvant chemotherapy consisting of anthracyclines and biological therapy with Herceptin (Trastuzumab – monoclonal humanized IgG1 antibodies, administered in HER2 + breast cancer). By cumulating the current clinical data with the therapeutic challenges of the anthracyclines (antitumoral effect vs cardiotoxicity), we are trying to encourage the multidisciplinary approach (oncology and cardiology), in order to reach the best therapeutic decision for each patient.

scholarly journals Advanced and futuristic approaches for breast cancer diagnosis

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Jayanti Mishra ◽  
Bhumika Kumar ◽  
Monika Targhotra ◽  
P. K. Sahoo
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Techniques ◽  
Main Body ◽  
Detection Techniques ◽  
Initial Stage ◽  
Common Causes ◽  
Delay In Treatment

Abstract Background Breast cancer is the most frequent cancer and one of the most common causes of death in women, impacting almost 2 million women each year. Tenacity or perseverance of breast cancer in women is very high these days with an extensive increasing rate of 3 to 5% every year. Along with hurdles faced during treatment of breast tumor, one of the crucial causes of delay in treatment is invasive and poor diagnostic techniques for breast cancer hence the early diagnosis of breast tumors will help us to improve its management and treatment in the initial stage. Main body Present review aims to explore diagnostic techniques for breast cancer that are currently being used, recent advancements that aids in prior detection and evaluation and are extensively focused on techniques that are going to be future of breast cancer detection with better efficiency and lesser pain to patients so that it helps to a physician to prevent delay in treatment of cancer. Here, we have discussed mammography and its advanced forms that are the need of current era, techniques involving radiation such as radionuclide methods, the potential of nanotechnology by using nanoparticle in breast cancer, and how the new inventions such as breath biopsy, and X-ray diffraction of hair can simply use as a prominent method in breast cancer early and easy detection tool. Conclusion It is observed significantly that advancement in detection techniques is helping in early diagnosis of breast cancer; however, we have to also focus on techniques that will improve the future of cancer diagnosis in like optical imaging and HER2 testing.

scholarly journals Factors Associated with “Survivor Identity” in Men with Breast Cancer

2021 ◽  
Vol 28 (3) ◽  
pp. 1696-1705
Author(s):  
Kathryn L. Dalton ◽  
Sheila N. Garland ◽  
Peggy Miller ◽  
Bret Miller ◽  
Cheri Ambrose ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Disease Type ◽  
Cancer Stage ◽  
Factors Associated ◽  
Logistic Regressions ◽  
Term Survivor ◽  
Diagnosis Age ◽  
Time Since Diagnosis

Cancer patients vary in their comfort with the label “survivor”. Here, we explore how comfortable males with breast cancer (BC) are about accepting the label cancer “survivor”. Separate univariate logistic regressions were performed to assess whether time since diagnosis, age, treatment status, and cancer stage were associated with comfort with the “survivor” label. Of the 70 males treated for BC who participated in the study, 58% moderately-to-strongly liked the term “survivor”, 26% were neutral, and 16% moderately-to-strongly disliked the term. Of the factors we explored, only a longer time since diagnosis was significantly associated with the men endorsing a survivor identity (OR = 1.02, p = 0.05). We discuss how our findings compare with literature reports on the comfort with the label “survivor” for women with BC and men with prostate cancer. Unlike males with prostate cancer, males with BC identify as “survivors” in line with women with BC. This suggests that survivor identity is more influenced by disease type and treatments received than with sex/gender identities.

Sign in / Sign up

Export Citation Format

Share Document